On the fly News and insights, exclusive to thefly.com



$22.73 /

+0.1 (+0.44%)


Oppenheimer starts Amarin with $7 target on 'rich' valuation, 'stale' M&A thesis

Oppenheimer analyst Leland Gershell initiated coverage of Amarin with an Underperform rating and $7 price target. The stock closed Tuesday up 13c to $22.73. Amarin's current valuation reflects expectations that, following near-term label expansion of sole omega-3 product Vascepa, the company's sales will inflect and grow to $2B-plus by 2024 and its operating margins will meaningfully improve, Gershell tells investors in a research note. The analyst, however, forecasts Amarin's sales growth to "underwhelm" and that "heavy selling costs" will impede its profitability. Furthermore, a 12-month stream of late-stage competitor data starting next month will increasingly weigh on shares as these products will offer superior profiles, adds Gershell. In addition, the analyst thinks the likelihood of Amarin getting acquired will only shrink with time. He views Amarin's valuation as "rich" and the M&A thesis as "stale."

  • 28


AMRN Amarin
$22.73 /

+0.1 (+0.44%)

11/19/19 Oppenheimer
Amarin initiated with an Underperform at Oppenheimer
11/19/19 Cantor Fitzgerald
Cantor sees wide use for Amarin's Vascepa regardless of label language
11/19/19 Jefferies
Jefferies still expects Amarin shares to rise toward $30
11/18/19 Jefferies
Amarin AHA data 'interesting,' but not relevant for approval, says Jefferies

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.